USPTO serial 98232757
CYTEGRITY
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- KEATING, MICHAEL P
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with CYTEGRITY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
CSL Behring Gene Therapy, Inc.
Pasadena, CA, US
CSL Behring Gene Therapy, Inc.
Pasadena, CA, US
CSL Behring Gene Therapy, Inc.
Pasadena, CA, US
CSL Behring Gene Therapy, Inc.
Pasadena, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Woldow
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP1055 THOMAS JEFFERSON ST. NWSUITE 400WASHINGTON, DC 20007Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Cell lines, being cells, for scientific and research use; Cells for scientific, laboratory or medical research; Biological preparations, namely, viral vectors and gene vectors for scientific, laboratory or medical research; Cell lines for clinical laboratory use; cell lines for scientific research, namely, cell lines for gene expression and for the synthesis of biological compounds; cells for scientific, laboratory, or medical research, namely, cells for gene expression systems and for the synthesis of biological compounds; viral vectors for use in science and industry | ACTIVE | — |
| 005 | Cell lines for medical purposes; Cells for medical or clinical use; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating cancer, tumors, genetic diseases, immunodeficiency conditions, stem cell transplantation, and transplant medicine; Biological preparations, namely, viral vectors and gene therapy vectors for therapeutic use and clinical use; Biological preparations, namely, viral vectors and gene therapy vectors for treating a wide range of diseases, illnesses or conditions; Cell lines for medical purposes, namely, cell therapy; Cell lines for medical purposes, namely, immunotherapy; Cell lines for medical purposes, namely, for use as therapeutics to repair, replace or preserve cells and tissues; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating genetically engineered tissues and for treating transplant conditions; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating viral and infectious diseases; Biological preparations, namely, viral vectors and gene therapy vectors for medical or clinical use for treating metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders; viral vectors for medical use relating to gene therapy; gene therapy vectors for medical use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CSL Behring Gene Therapy, Inc.
- Other trademarks owned by CSL Behring Gene Therapy, Inc.
- Other trademarks owned by CSL Behring Gene Therapy, Inc.
- Other trademarks owned by CSL Behring Gene Therapy, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named CYTEGRITY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 11, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 11, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 11, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 11, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 11, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 11, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 25, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 11, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 11, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 11, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 11, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 14, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 14, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 17, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 11, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 11, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 11, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 11, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Sep 11, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jun 13, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 5, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 25, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 24, 2023 | NWAP | NEW APPLICATION ENTERED | — |